Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
Biomea Fusion (BMEA) Stock Price & Analysis
577 Followers
BMEA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.61 - $23.07
Previous Close$5.04
Volume226.45K
Average Volume (3M)1.30M
Market Cap
$181.16M
Enterprise Value$47.33M
Total Cash (Recent Filing)$144.92M
Total Debt (Recent Filing)$11.09M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Jul 29, 2024EPS Estimate
-$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding35,944,584
10 Day Avg. Volume4,172,668
30 Day Avg. Volume1,302,716
Standard Deviation0.39
R-Squared0.00234
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$20.56Price Target Upside307.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Biomea Fusion News
Bulls Say, Bears Say
Bulls Say
Clinical DataCOVALENT-111 reveals BMF-219’s skills as a long-distance runner; sustained glycemic control at 26-week follow-up.
Safety ProfileBMF-219 presents a generally well-tolerated safety profile with no SAEs observed.
Strategic ExpansionKura announced plans to expand into diabetes and presented preclinical data at ADA'24.
Bears Say
Clinical HoldBiomea's diabetes trials are on clinical hold due to unexpected liver toxicities.
Safety ConcernsSigns of liver toxicity put BMF-219 on clinical hold in diabetes trials.
Stock PerformanceAfter BMEA’s clinical hold announcement, stock was down 63% vs flat SP50.
---
Ownership Overview
60.09% Insiders
17.46% Mutual Funds
8.02% Other Institutional Investors
14.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $3.61 and its highest was $23.07 in the past 12 months.
What is Biomea Fusion’s market cap?
Currently, no data Available
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Jul 29, 2024 which is in 8 days.
How were Biomea Fusion’s earnings last quarter?
Currently, no data Available
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -$1.08.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 35,944,584 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biomea Fusion?
Among the largest hedge funds holding Biomea Fusion’s share is Baker Bros Advisors LP. It holds Biomea Fusion’s shares valued at 32M.
---
Biomea Fusion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.56 (307.94% Upside)
$20.56 (307.94% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 39.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $55.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.42%
12-Months-Change
Fundamentals
Return on Equity
-116.52%
Trailing 12-Months
Asset Growth
49.59%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
---
BMEA Stock 12 Month Forecast
Average Price Target
$20.56
▲(307.94% Upside)
Technical Analysis
Fate Therapeutics
―
Bioxcel Therapeutics
―
Corbus Pharmaceuticals
―
Eton Pharmaceuticals
―
Best Analysts Covering BMEA
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-39.34%
reiterated a buy rating last month
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -39.34% per trade.
---